These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
877 related articles for article (PubMed ID: 31115744)
1. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo. Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594 [TBL] [Abstract][Full Text] [Related]
3. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner. Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183 [TBL] [Abstract][Full Text] [Related]
5. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models. Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715 [TBL] [Abstract][Full Text] [Related]
6. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML. Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848 [TBL] [Abstract][Full Text] [Related]
7. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002 [TBL] [Abstract][Full Text] [Related]
8. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1. Luedtke DA; Su Y; Liu S; Edwards H; Wang Y; Lin H; Taub JW; Ge Y J Cell Mol Med; 2018 Dec; 22(12):6099-6111. PubMed ID: 30596398 [TBL] [Abstract][Full Text] [Related]
11. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471 [TBL] [Abstract][Full Text] [Related]
12. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Luedtke DA; Su Y; Ma J; Li X; Buck SA; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Lin H; Taub JW; Ge Y Signal Transduct Target Ther; 2020 Feb; 5(1):17. PubMed ID: 32296028 [TBL] [Abstract][Full Text] [Related]
14. Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway. Tauchi T; Moriya S; Okabe S; Kazama H; Miyazawa K; Takano N PLoS One; 2024; 19(7):e0307662. PubMed ID: 39052583 [TBL] [Abstract][Full Text] [Related]
15. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia. Wang X; Mak PY; Mu H; Tao W; Rao A; Visweswaran R; Ruvolo V; Pachter JA; Weaver DT; Andreeff M; Xu B; Carter BZ Mol Cancer Ther; 2020 Aug; 19(8):1636-1648. PubMed ID: 32404407 [TBL] [Abstract][Full Text] [Related]
16. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance. Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916 [TBL] [Abstract][Full Text] [Related]
17. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML. Ewald L; Dittmann J; Vogler M; Fulda S Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941 [TBL] [Abstract][Full Text] [Related]
18. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395 [TBL] [Abstract][Full Text] [Related]
19. Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Niu X; Zhao J; Ma J; Xie C; Edwards H; Wang G; Caldwell JT; Xiang S; Zhang X; Chu R; Wang ZJ; Lin H; Taub JW; Ge Y Clin Cancer Res; 2016 Sep; 22(17):4440-51. PubMed ID: 27103402 [TBL] [Abstract][Full Text] [Related]
20. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax. Satta T; Li L; Chalasani SL; Hu X; Nkwocha J; Sharma K; Kmieciak M; Rahmani M; Zhou L; Grant S Clin Cancer Res; 2023 Apr; 29(7):1332-1343. PubMed ID: 36652560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]